LRG1-Targeted Nintedanib Delivery for Enhanced Renal Fibrosis Mitigation
Source abstract
Abstract
Renal fibrosis lacks effective nephroprotective drugs in clinical settings due to poor accumulation of therapeutic agents in damaged kidneys, underscoring the urgent need for advanced renal-targeted delivery systems. Herein, we exploited the significantly increased expression of the leucine-rich α-2 glycoprotein 1 (LRG1) protein during renal fibrosis to develop a novel drug delivery system. Our engineered nanocarrier, DEN NM, preferentially targets fibrotic kidneys via the decorated ET peptide’s high affinity for LRG1. Once internalized by damaged renal cells, DEN NM releases its encapsulated nintedanib, triggered by the active caspase-3 protease, disrupting the nanomedicine’s structural integrity. The released nintedanib effectively reduces the level of expression of the extracellular matrix and impedes the progression of renal fibrosis by inhibiting the transforming growth factor-β (TGF-β)-Smad2/3 pathway. Our comprehensive in vitro and in vivo studies validate DEN NM ’s antifibrotic efficacy, emphasizing LRG1’s potential in renal targeted drug delivery and introducing an innovative approach to nanomedicine for treating renal fibrosis.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Clusterin in disease pathology · Iron Metabolism and Disorders · Chronic Kidney Disease and Diabetes
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Henan Institute of Advanced Technology, Zhengzhou University, Zhengzhou 450003, China
Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China
Funding
China Postdoctoral Science Foundation · National Natural Science Foundation of China
References (35)
Show source-provided references
1. 10.1152/physrev.00027.202210.1152/physrev.00027.2022 ↗
2. 10.1038/ki.2009.8610.1038/ki.2009.86 ↗
3. 10.1172/JCI7226710.1172/JCI72267 ↗
4. 10.1146/annurev-physiol-022516-03422710.1146/annurev-physiol-022516-034227 ↗
5. 10.1038/s41581-022-00590-z10.1038/s41581-022-00590-z ↗
6. 10.1038/s41392-023-01379-710.1038/s41392-023-01379-7 ↗
7. 10.1016/j.kint.2018.08.03610.1016/j.kint.2018.08.036 ↗
8. 10.1111/j.1600-6143.2012.04101.x10.1111/j.1600-6143.2012.04101.x ↗
9. 10.1038/nrd.2016.6710.1038/nrd.2016.67 ↗
10. 10.1183/09031936.0017491410.1183/09031936.00174914 ↗
11. 10.1056/NEJMoa140258410.1056/NEJMoa1402584 ↗
12. 10.1042/CS2019024910.1042/CS20190249 ↗
13. 10.1155/2020/386719810.1155/2020/3867198 ↗
14. 10.1038/srep4454510.1038/srep44545 ↗
15. 10.1042/CS2017013410.1042/CS20170134 ↗
16. 10.3390/ijms1706097210.3390/ijms17060972 ↗
17. 10.1172/JCI7166810.1172/JCI71668 ↗
18. 10.1159/00050967010.1159/000509670 ↗
19. 10.31635/ccschem.022.20220240410.31635/ccschem.022.202202404 ↗
20. 10.1038/s41578-021-00315-x10.1038/s41578-021-00315-x ↗
21. 10.1002/adma.20180820010.1002/adma.201808200 ↗
22. 10.1021/acs.molpharmaceut.1c0051110.1021/acs.molpharmaceut.1c00511 ↗
23. 10.1002/med.2153210.1002/med.21532 ↗
24. 10.1016/j.jconrel.2021.04.01610.1016/j.jconrel.2021.04.016 ↗
25. 10.1046/j.1523-1755.2000.00314.x10.1046/j.1523-1755.2000.00314.x ↗
26. 10.1126/sciadv.abb742210.1126/sciadv.abb7422 ↗
27. 10.1002/EXP.2022014810.1002/EXP.20220148 ↗
28. 10.1186/s12929-022-00790-610.1186/s12929-022-00790-6 ↗
29. 10.1016/j.kint.2021.10.02310.1016/j.kint.2021.10.023 ↗
30. 10.1016/j.ajps.2024.10094110.1016/j.ajps.2024.100941 ↗
31. 10.1007/s12274-023-6268-810.1007/s12274-023-6268-8 ↗
32. 10.1021/acs.analchem.7b0279010.1021/acs.analchem.7b02790 ↗
33. 10.1002/adma.20140471510.1002/adma.201404715 ↗
34. 10.1021/acsnano.5b0506610.1021/acsnano.5b05066 ↗
35. 10.1042/CS2017013410.1042/CS20170134 ↗